GSK boosts oncology rebuild with $11 billion Nuvalent acquisition
British drugmaker GSK has capped its Project Nashville oncology rebuild with an 11 billion dollar acquisition of Nuvalent, Investing.com reported. The deal aims to expand GSK's pipeline in targeted lung cancer therapies, including ROS1 and ALK inhibitors.
Investing.com US4 h agoGSK NUVL